Screener / SEC EDGAR /CIK 0001635088 /10-K filed May 20, 2026, compared with May 29, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Roivant Sciences Ltd. ROIV

Compare with peers Embed

ROIV among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
-71.6%153rd of 155 · median +10.5%
Net margin
-4.1%15.3%
-838.2%153rd of 154 · median 6.8%
Return on equity
-5.2%18.5%
-8.6%110th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-81.2%136th of 145 · median 10.0%

ROIV and 9 peers, year by year

The 9 Health care companies closest to ROIV in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthOperating marginNet marginFCF marginReturn on equityDebt / equity
ROIV Roivant Sciences Ltd. FY2026 $8.3M−71.6%n/mn/mn/m−6.6%-
IDYA IDEAYA Biosciences, Inc. FY2025 $218.7Mn/m−72.8%−52.0%−33.6%−11.1%-
OCUL Ocular Therapeutix, Inc FY2025 $52.0M−18.5%−519.8%−511.9%−417.5%−40.6%0.11
CRSP CRISPR Therapeutics AG FY2025 $3.5M−90.6%n/mn/mn/m−30.3%0.00
RXRX Recursion Pharmaceuticals, Inc. FY2025 $74.7M+26.9%−867.9%−863.4%−506.5%−57.0%0.02
CGON CG Oncology, Inc. FY2025 $4.0M+255%n/mn/mn/m−21.4%0.00
SRRK Scholar Rock Holding Corp FY2025 $0----−154.0%0.41
KYMR Kymera Therapeutics, Inc. FY2025 $39.2M−16.7%−891.1%−794.0%−597.6%−19.7%-
CYTK Cytokinetics Inc FY2025 $88.0M+377%−695.4%−891.6%−607.5%n/mn/m
AGIO Agios Pharmaceuticals, Inc. FY2025 $54.0M+48.0%−873.9%−764.0%−698.3%−34.6%-

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2021 to FY2026 · 10-K XBRL

ROIVRoivant Sciences Ltd.
FY2021 revenue $23.8MFY2022 revenue $55.3MFY2023 revenue $31.5MFY2024 revenue $32.7MFY2025 revenue $29.1MFY2026 revenue $8.3M FY2025 net margin −592.0% FY2021FY2026
Revenue$8.3M Growth−71.6% Net margin−592.0%
IDYAIDEAYA Biosciences, Inc.
FY2021 revenue $27.9MFY2022 revenue $50.9MFY2023 revenue $23.4MFY2024 revenue $7.0MFY2025 revenue $218.7M FY2021 net margin −178.1%FY2022 net margin −115.2%FY2023 net margin −483.0%FY2025 net margin −52.0% FY2021FY2026
Revenue$218.7M Growth−70.1% Net margin−52.0%
OCULOcular Therapeutix, Inc
FY2021 revenue $43.5MFY2022 revenue $51.5MFY2023 revenue $58.4MFY2024 revenue $63.7MFY2025 revenue $52.0M FY2021 net margin −15.1%FY2022 net margin −138.0%FY2023 net margin −138.1%FY2024 net margin −303.7%FY2025 net margin −511.9% FY2021FY2026
Revenue$52.0M Growth−18.5% Net margin−511.9%
CRSPCRISPR Therapeutics AG
FY2021 revenue $915.0MFY2022 revenue $1.2MFY2023 revenue $371.2MFY2024 revenue $37.3MFY2025 revenue $3.5M FY2021 net margin 41.3%FY2023 net margin −41.4%FY2024 net margin −981.5% FY2021FY2026
Revenue$3.5M Growth−90.6% Net margin−981.5%
RXRXRecursion Pharmaceuticals, Inc.
FY2021 revenue $10.2MFY2022 revenue $39.8MFY2023 revenue $44.6MFY2024 revenue $58.8MFY2025 revenue $74.7M FY2022 net margin −601.0%FY2023 net margin −736.0%FY2024 net margin −788.0%FY2025 net margin −863.4% FY2021FY2026
Revenue$74.7M Growth+26.9% Net margin−863.4%
CGONCG Oncology, Inc.
FY2023 revenue $204KFY2024 revenue $1.1MFY2025 revenue $4.0M FY2021FY2026
Revenue$4.0M Growth+255% Net margin-
SRRKScholar Rock Holding Corp
FY2021 revenue $18.8MFY2022 revenue $33.2M FY2021 net margin −700.5%FY2022 net margin −405.2% FY2021FY2026
Revenue$0 Growth+76.4% Net margin−405.2%
KYMRKymera Therapeutics, Inc.
FY2021 revenue $72.8MFY2022 revenue $46.8MFY2023 revenue $78.6MFY2024 revenue $47.1MFY2025 revenue $39.2M FY2021 net margin −137.6%FY2022 net margin −330.6%FY2023 net margin −187.0%FY2024 net margin −475.6%FY2025 net margin −794.0% FY2021FY2026
Revenue$39.2M Growth−16.7% Net margin−794.0%
CYTKCytokinetics Inc
FY2021 revenue $70.4MFY2022 revenue $94.6MFY2023 revenue $7.5MFY2024 revenue $18.5MFY2025 revenue $88.0M FY2021 net margin −305.7%FY2022 net margin −411.2%FY2025 net margin −891.6% FY2021FY2026
Revenue$88.0M Growth+377% Net margin−891.6%
AGIOAgios Pharmaceuticals, Inc.
FY2022 revenue $14.2MFY2023 revenue $26.8MFY2024 revenue $36.5MFY2025 revenue $54.0M FY2025 net margin −764.0% FY2021FY2026
Revenue$54.0M Growth+48.0% Net margin−764.0%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2021 to FY2026

Revenue as reported in the 10-K.

$0 $915.0M FY2021FY2022FY2023FY2024FY2025FY2026 IDYA: $27.9M, $50.9M, $23.4M, $7.0M, $218.7M, - IDYA OCUL: $43.5M, $51.5M, $58.4M, $63.7M, $52.0M, - OCUL CRSP: $915.0M, $1.2M, $371.2M, $37.3M, $3.5M, - CRSP RXRX: $10.2M, $39.8M, $44.6M, $58.8M, $74.7M, - RXRX CGON: -, -, $204K, $1.1M, $4.0M, - CGON SRRK: $18.8M, $33.2M, -, -, $0, - SRRK KYMR: $72.8M, $46.8M, $78.6M, $47.1M, $39.2M, - KYMR CYTK: $70.4M, $94.6M, $7.5M, $18.5M, $88.0M, - CYTK AGIO: $0, $14.2M, $26.8M, $36.5M, $54.0M, - AGIO ROIV: $23.8M, $55.3M, $31.5M, $32.7M, $29.1M, $8.3M ROIV
ROIV is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $915.0M. A gap is a year with no number. A ring marks where a line starts: CGON has no earlier 10-K here. ROIV: the line is cut where a later 10-K restates the year before (a spin-off or a merger), so the two years are not the same company.

Sales growth, FY2021 to FY2026

Revenue against the fiscal year before.

−99.9% +458% FY2021FY2022FY2023FY2024FY2025FY2026 IDYA: +43.0%, +82.3%, −54.1%, −70.1%, n/m, - IDYA OCUL: +150%, +18.3%, +13.5%, +9.0%, −18.5%, - OCUL CRSP: n/m, −99.9%, n/m, −89.9%, −90.6%, - CRSP RXRX: +157%, +291%, +11.9%, +32.0%, +26.9%, - RXRX CGON: -, -, -, +458%, +255%, - CGON SRRK: +22.2%, +76.4%, -, -, -, - SRRK KYMR: +114%, −35.7%, +67.8%, −40.1%, −16.7%, - KYMR CYTK: +26.2%, +34.3%, −92.0%, +145%, +377%, - CYTK AGIO: -, -, +88.4%, +36.1%, +48.0%, - AGIO ROIV: -, +132%, +10.8%, +3.8%, −11.2%, −71.6% ROIV
ROIV is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −99.9% to +458%. A gap is a year with no number. A ring marks where a line starts: ROIV, CRSP, CGON, AGIO have no earlier 10-K here.

Operating margin, FY2021 to FY2026

Operating income / revenue.

−891.1% 40.8% FY2021FY2022FY2023FY2024FY2025FY2026 IDYA: −179.9%, −122.7%, −574.9%, n/m, −72.8%, - IDYA OCUL: −179.3%, −152.7%, −141.0%, −269.6%, −519.8%, - OCUL CRSP: 40.8%, n/m, −60.0%, n/m, n/m, - CRSP RXRX: n/m, −616.7%, −785.3%, −814.1%, −867.9%, - RXRX SRRK: −690.5%, −404.8%, -, -, -, - SRRK KYMR: −138.0%, −344.4%, −210.6%, −555.8%, −891.1%, - KYMR CYTK: −264.5%, −342.8%, n/m, n/m, −695.4%, - CYTK AGIO: -, n/m, n/m, n/m, −873.9%, - AGIO
ROIV is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −891.1% to 40.8%. A gap is a year with no number. A ring marks where a line starts: RXRX, AGIO have no earlier 10-K here.

Net margin, FY2021 to FY2026

Net income / revenue.

−981.5% 41.3% FY2021FY2022FY2023FY2024FY2025FY2026 IDYA: −178.1%, −115.2%, −483.0%, n/m, −52.0%, - IDYA OCUL: −15.1%, −138.0%, −138.1%, −303.7%, −511.9%, - OCUL CRSP: 41.3%, n/m, −41.4%, −981.5%, n/m, - CRSP RXRX: n/m, −601.0%, −736.0%, −788.0%, −863.4%, - RXRX SRRK: −700.5%, −405.2%, -, -, -, - SRRK KYMR: −137.6%, −330.6%, −187.0%, −475.6%, −794.0%, - KYMR CYTK: −305.7%, −411.2%, n/m, n/m, −891.6%, - CYTK AGIO: -, n/m, n/m, n/m, −764.0%, - AGIO ROIV: n/m, n/m, n/m, n/m, −592.0%, n/m ROIV
ROIV is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −981.5% to 41.3%. A gap is a year with no number. A ring marks where a line starts: ROIV, RXRX, AGIO have no earlier 10-K here.

Free cash flow, FY2021 to FY2026

Cash from operations minus capital spending.

−$856.1M $457.3M FY2021FY2022FY2023FY2024FY2025FY2026 IDYA: −$58.4M, −$90.6M, −$117.6M, −$251.4M, −$73.5M, - IDYA OCUL: −$66.7M, −$63.3M, −$76.3M, −$136.0M, −$216.9M, - OCUL CRSP: $457.3M, −$532.9M, −$269.8M, −$144.7M, −$345.9M, - CRSP RXRX: −$198.4M, −$120.6M, −$299.7M, −$372.9M, −$378.3M, - RXRX CGON: -, -, -, −$78.9M, −$132.5M, - CGON SRRK: −$132.0M, −$133.8M, −$145.3M, −$201.0M, −$300.6M, - SRRK KYMR: −$130.5M, −$155.9M, −$137.3M, −$207.3M, −$234.3M, - KYMR CYTK: −$191.4M, −$310.9M, −$415.7M, −$399.8M, −$534.8M, - CYTK AGIO: −$413.1M, −$314.4M, −$297.1M, −$391.5M, −$377.3M, - AGIO ROIV: −$557.9M, −$695.2M, −$856.1M, −$766.6M, −$844.0M, −$758.6M ROIV
ROIV is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$856.1M to $457.3M. A gap is a year with no number. A ring marks where a line starts: CGON has no earlier 10-K here.

FCF margin, FY2021 to FY2026

Free cash flow / revenue.

−701.7% 50.0% FY2021FY2022FY2023FY2024FY2025FY2026 IDYA: −209.1%, −177.9%, −502.9%, n/m, −33.6%, - IDYA OCUL: −153.4%, −123.0%, −130.6%, −213.4%, −417.5%, - OCUL CRSP: 50.0%, n/m, −72.7%, −387.7%, n/m, - CRSP RXRX: n/m, −302.6%, −672.4%, −633.7%, −506.5%, - RXRX SRRK: −701.7%, −403.0%, -, -, -, - SRRK KYMR: −179.2%, −333.0%, −174.7%, −440.5%, −597.6%, - KYMR CYTK: −271.8%, −328.6%, n/m, n/m, −607.5%, - CYTK AGIO: -, n/m, n/m, n/m, −698.3%, - AGIO
ROIV is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −701.7% to 50.0%. A gap is a year with no number. A ring marks where a line starts: RXRX, AGIO have no earlier 10-K here.

Return on equity, FY2021 to FY2026

Net income / shareholders' equity at the year end.

−154.0% 124.2% FY2021FY2022FY2023FY2024FY2025FY2026 IDYA: −16.5%, −16.8%, −18.2%, −25.9%, −11.1%, - IDYA OCUL: −7.4%, n/m, −88.6%, −61.4%, −40.6%, - OCUL CRSP: 15.7%, −34.7%, −8.2%, −19.0%, −30.3%, - CRSP RXRX: −34.3%, −49.3%, −70.8%, −44.8%, −57.0%, - RXRX CGON: -, -, n/m, −12.0%, −21.4%, - CGON SRRK: −76.6%, −51.7%, −73.6%, −66.8%, −154.0%, - SRRK KYMR: −21.8%, −31.6%, −37.2%, −26.8%, −19.7%, - KYMR CYTK: −88.3%, n/m, n/m, n/m, n/m, - CYTK AGIO: 124.2%, −21.1%, −43.4%, 43.7%, −34.6%, - AGIO ROIV: −45.0%, −51.0%, −87.2%, 72.9%, −3.7%, −6.6% ROIV
ROIV is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −154.0% to 124.2%. A gap is a year with no number. A ring marks where a line starts: CGON has no earlier 10-K here.

Debt / equity, FY2021 to FY2026

Total debt / shareholders' equity at the year end.

0.00 0.72 FY2021FY2022FY2023FY2024FY2025FY2026 OCUL: 0.28, 0.71, 0.72, 0.22, 0.11, - OCUL CRSP: -, -, -, -, 0.00, - CRSP RXRX: 0.00, 0.00, 0.00, 0.03, 0.02, - RXRX CGON: -, -, -, 0.00, 0.00, - CGON SRRK: 0.31, 0.20, 0.23, 0.14, 0.41, - SRRK CYTK: 0.19, n/m, n/m, n/m, n/m, - CYTK ROIV: 0.09, 0.13, 0.32, 0.07, -, - ROIV
ROIV is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 0.72. A gap is a year with no number. A ring marks where a line starts: CRSP, CGON have no earlier 10-K here.
CompanyFY2021FY2022FY2023FY2024FY2025FY2026
ROIV Mar 0.090.130.320.07--
IDYA Dec ------
OCUL Dec 0.280.710.720.220.11-
CRSP Dec ----0.00-
RXRX Dec 0.000.000.000.030.02-
CGON Dec ---0.000.00-
SRRK Dec 0.310.200.230.140.41-
KYMR Dec ------
CYTK Dec 0.19n/mn/mn/mn/m-
AGIO Dec ------
Peer median0.240.200.230.080.02-

EPS (diluted), FY2021 to FY2026

Diluted earnings per share, on today's share count after splits.

−$15.65 $26.55 FY2021FY2022FY2023FY2024FY2025FY2026 IDYA: −$1.41, −$1.42, −$1.96, −$3.36, −$1.28, - IDYA OCUL: −$0.98, −$0.97, −$1.02, −$1.22, −$1.42, - OCUL CRSP: $4.70, −$8.36, −$1.94, −$4.34, −$6.47, - CRSP RXRX: −$1.49, −$1.36, −$1.58, −$1.69, −$1.44, - RXRX CGON: -, -, −$15.65, −$1.41, −$2.08, - CGON SRRK: −$3.59, −$2.26, −$1.99, −$2.47, −$3.29, - SRRK KYMR: −$2.09, −$2.87, −$2.52, −$2.98, −$3.69, - KYMR CYTK: −$2.80, −$4.33, −$5.45, −$5.26, −$6.54, - CYTK AGIO: $26.55, −$4.23, −$6.33, $11.64, −$7.12, - AGIO ROIV: −$1.28, −$1.26, −$1.42, $5.23, −$0.24, −$0.54 ROIV
ROIV is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$15.65 to $26.55. A gap is a year with no number. A ring marks where a line starts: CGON has no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out ROIV and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: ROIV's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.